A strategy to discover decoy chemokine ligands with an anti-inflammatory activity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Abboud, Dayana ^a   Daubeuf, François ^a   Do, Quoc Tuan ^b   Utard, Valérie ^a   Villa, Pascal ^a   Haiech, Jacques ^a   Bonnet, Dominique ^a   Hibert, Marcel ^a   Bernard, Philippe ^b   Galzi, Jean Luc ^a   Frossard, Nelly ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b GreenPharma SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CCL17 PROTEIN, HUMAN; CCL22 PROTEIN, HUMAN; CHEMOKINE; CHEMOKINE RECEPTOR CCR4; MACROPHAGE DERIVED CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL; ASTHMA; BAGG ALBINO MOUSE; CELL MOTION; CHEMOTAXIS; DENDRITIC CELL; DRUG EFFECTS; EOSINOPHIL; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; MOLECULAR MODEL; MOUSE; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CELL MOVEMENT; CHEMOKINE CCL17; CHEMOKINE CCL22; CHEMOKINES; CHEMOTAXIS; DENDRITIC CELLS; EOSINOPHILS; HEK293 CELLS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; RECEPTORS, CCR4; TH2 CELLS;

EID: 84943329278     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14746     Document Type: Article

References (52)

1. Borsig, L., Wolf, M. J., Roblek, M., Lorentzen, A., Heikenwalder, M. Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 33, 3217-24 (2014).
2. Horuk, R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 8, 23-33 (2009).
3. Kenakin, T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4, 919-27 (2005).
4. Deruaz, M. et al. Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models. FEBS J 280, 4876-87 (2013).
5. Webb, L. M., Smith, V. P., Alcami, A. The gammaherpesvirus chemokine binding protein can inhibit the interaction of chemokines with glycosaminoglycans. FASEB J 18, 571-3 (2004).
6. Mossman, K. et al. Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215, 17-30 (1996).
7. Blanchetot, C. et al. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J Biol Chem 288, 25173-82 (2013).
8. Scalley-Kim, M. L. et al. A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation. PLoS One 7, e43332 (2012).
9. Hoellenriegel, J. et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123, 1032-9 (2014).
10. Hachet-Haas, M. et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem 283, 23189-99 (2008).
11. Naumann, U. et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 5, e9175 (2010).
12. Imai, T. et al. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 272, 15036-42 (1997).
13. Mantovani, A., Gray, P. A., Van Damme, J., Sozzani, S. Macrophage-derived chemokine (MDC). J Leukoc Biol 68, 400-4 (2000).
14. Perros, F., Hoogsteden, H. C., Coyle, A. J., Lambrecht, B. N., Hammad, H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy 64, 995-1002 (2009).
15. Pease, J. E. Asthma, allergy and chemokines. Curr Drug Targets 7, 3-12 (2006).
16. Homey, B., Steinhoff, M., Ruzicka, T., Leung, D. Y. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118, 178-89 (2006).
17. Panina-Bordignon, P. et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 107, 1357-64 (2001).
18. Vijayanand, P. et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 184, 4568-74 (2010).
19. Vestergaard, C. et al. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+ CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 115, 640-6 (2000).
20. Fujita, H. et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. J Allergy Clin Immunol 128, 574-82 e1-12 (2011).
21. Tamaki, K. et al. Serum levels of CCL17/TARC in various skin diseases. J Dermatol 33, 300-2 (2006).
22. Stutte, S. et al. Requirement of CCL17 for CCR7-and CXCR4-dependent migration of cutaneous dendritic cells. Proc Natl Acad Sci USA 107, 8736-41 (2010).
23. Conroy, D. M. et al. CCR4 blockade does not inhibit allergic airways inflammation. J Leukoc Biol 74, 558-63 (2003).
24. Chvatchko, Y. et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 191, 1755-64 (2000).
25. Santulli-Marotto, S. et al. Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung. PLoS One 8, e81465 (2013).
26. Kawasaki, S. et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol 166, 2055-62 (2001).
27. Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D., Bourne, H. R. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363, 274-6 (1993).
28. Proudfoot, A. E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2, 106-15 (2002).
29. Zhang, J. H., Chung, T. D., Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73 (1999).
30. Arakaki, R. et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 73, 1719-23 (1999).
31. Yokoyama, K. et al. Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines. Bioorg Med Chem 16, 7968-74 (2008).
32. Asojo, O. A., Boulegue, C., Hoover, D. M., Lu, W., Lubkowski, J. Structures of thymus and activation-regulated chemokine (TARC). Acta Crystallogr D Biol Crystallogr 59, 1165-73 (2003).
33. Mariani, M., Lang, R., Binda, E., Panina-Bordignon, P., D'Ambrosio, D. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 34, 231-40 (2004).
34. Viney, J. M. et al. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. J Immunol 192, 3419-27 (2014).
35. Ajram, L. et al. Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. Eur J Pharmacol 729, 75-85 (2014).
36. Yoshie, O. et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99, 1505-11 (2002).
37. Fujimoto, S. et al. CCR4 and CCR10 are expressed on epidermal keratinocytes and are involved in cutaneous immune reaction. Cytokine 44, 172-8 (2008).
38. Banner, K. H., Page, C. P. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 8, 996-1000 (1995).
39. Cryer, B., Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104, 413-21 (1998).
40. Teran, L. M. CCL chemokines and asthma. Immunol Today 21, 235-42 (2000).
41. Neighbour, H. et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 44, 508-16 (2014).
42. Alcami, A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3, 36-50 (2003).
43. Deruaz, M. et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 205, 2019-31 (2008).
44. Otte, M. et al. CXCL14 is no direct modulator of CXCR4. FEBS Lett 588, 4769-75 (2014).
45. Shaw, A. K. et al. TGFbeta Signaling in Myeloid Cells Regulates Mammary Carcinoma Cell Invasion through Fibroblast Interactions. PLoS One 10, e0117908 (2015).
46. Garcia-Perez, J. et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 286, 33409-21 (2011).
47. Struyf, S. et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 161, 2672-5 (1998).
48. Vollmer, J. Y., Alix, P., Chollet, A., Takeda, K., Galzi, J. L. Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors. J Biol Chem 274, 37915-22 (1999).
49. Thompson, J. D., Higgins, D. G., Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 4673-80 (1994).
50. Combet, C., Blanchet, C., Geourjon, C., Deleage, G. NPS@: network protein sequence analysis. Trends Biochem Sci 25, 147-50 (2000).
51. Jain, A. N. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21, 281-306 (2007).
52. Gasparik, V. et al. Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo. ACS Med Chem Lett 3, 10-4 (2012).